<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20221205056716N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-03-11</date_registration>
      <primary_sponsor>Qazvin University of Medical Sciences</primary_sponsor>
      <public_title>ٍٍEffect of Caffeine injection on pain after Cholecystectomy</public_title>
      <acronym></acronym>
      <scientific_title>The effect of intravenous injection of Caffeine on reducing pain after laparoscopic Cholecystectomy</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-05-05</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/67219</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: The method of random allocation in this study is Balanced Block Randomization.
6 blocks AABB- ABAB_ ABBA- BBAA- BABA_ BAAB are numbered based on 1 to 6 and numbers 1 to 6 are selected from the table of random numbers and placed together. Then they are replaced with numbered blocks, Blinding description: The anesthesiologist receives the drugs which are coded in closed envelopes and injects them into the patients. Coding is done by one of the colleagues of the project and the doctor, anesthesiologist, analyzer, and patient are blinded.</study_design>
      <phase>3</phase>
      <hc_freetext>Patients undergoing laparoscopic cholecystectomy.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: After entering the operating room, the patients undergo laparoscopic cholecystectomy under general anesthesia. After entering recovery, the experimental group was given caffeine injection drug by the anesthesiologist as an analgesic with a dose of 1 mg on a medicinal plant with medicinal characteristics: caffeine citrate 10 mg (3 ml) from Kimia drug company - maximum 60 mg per dose. It is injected intravenously to reduce pain. The pain level of the patient is recorded 10, 30, and 60 minutes after the intervention by a trained doctor or nurse. After the necessary coordination with the surgeon and the recovery nurses, for pain intensity between 4 and 6, 0.25 mg/kg of Pethidine, and for intensity Pain between 7 and 10, 0.5 mg/kg of Pethidine is injected and recorded in the patient's file. Intervention 2: Control group: After entering the operating room, the patients undergo laparoscopic cholecystectomy under general anesthesia. After entering recovery, 3cc of normal saline is injected intravenously into the control group. The pain level of the patient is recorded 10, 30, and 60 minutes after the intervention by a trained doctor or nurse. After the necessary coordination with the surgeon and the recovery nurses, for pain intensity between 4 and 6, 0.25 mg/kg of pethidine, and for intensity Pain between 7 and 10, 0.5 mg/kg of pethidine is injected and recorded in the patient's file.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All data can be shared after individuals are de-identified

When:
Access starts 6 months after results are published

To whom:
The data will be available to researchers working in academic and scientific institutions

Conditions:
Any kind of analysis on the delivered data is allowed

Where to obtain:
Refer to Dr. Shabnam's email "tikokhan@yahoo.com"

How to obtain:
After publishing the article, the applicant can send a clear request to the author to access the data by sending an email. So, after reviewing the request within 2 weeks, access to data and information is allowed.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mohammadreza Shabnam</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Bahonar street</address>
        <city>Qazvin</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>34199-15315</zip>
        <telephone>+98 28 3333 6001</telephone>
        <email>tikokhan@yahoo.com</email>
        <affiliation>Qazvin University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mohammadreza Shabnam</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>22 Bahman Blvd, Tavon Square, Elahiye Quay, Minodar Town</address>
        <city>Qazvin</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>34199-15315</zip>
        <telephone>+98 28 3333 6001</telephone>
        <email>tikokhan@yahoo.com</email>
        <affiliation>Qazvin University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age range 15-60 years
Candidate for Cholecystectomy surgery
Informed consent</inclusion_criteria>
      <agemin>15 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Pregnancy and breastfeeding and abortion less than 3 months
Hyperthyroidism
History of smoking, alcohol and drugs
Chronic mental and physical illness (Schizophrenia, Diabetes, etc.)
Vision and hearing problems and other disabilities
Corticosteroids, Antihistamines, and painkillers consumption for a long time (at least 2 months)
Allergy to Caffeine and Pethidine
History of surgery</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>K80</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Cholelithiasis</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: After entering the operating room, the patients undergo laparoscopic cholecystectomy under general anesthesia. After entering recovery, the experimental group was given caffeine injection drug by the anesthesiologist as an analgesic with a dose of 1 mg on a medicinal plant with medicinal characteristics: caffeine citrate 10 mg (3 ml) from Kimia drug company - maximum 60 mg per dose. It is injected intravenously to reduce pain. The pain level of the patient is recorded 10, 30, and 60 minutes after the intervention by a trained doctor or nurse. After the necessary coordination with the surgeon and the recovery nurses, for pain intensity between 4 and 6, 0.25 mg/kg of Pethidine, and for intensity Pain between 7 and 10, 0.5 mg/kg of Pethidine is injected and recorded in the patient's file.</i_keyword>
      <i_keyword>Control group: After entering the operating room, the patients undergo laparoscopic cholecystectomy under general anesthesia. After entering recovery, 3cc of normal saline is injected intravenously into the control group. The pain level of the patient is recorded 10, 30, and 60 minutes after the intervention by a trained doctor or nurse. After the necessary coordination with the surgeon and the recovery nurses, for pain intensity between 4 and 6, 0.25 mg/kg of pethidine, and for intensity Pain between 7 and 10, 0.5 mg/kg of pethidine is injected and recorded in the patient's file</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain level after laparoscopic cholecystectomy. Timepoint: 10, 30 and 60 minutes after the operation. Method of measurement: Ruler-like grading system (Visual Analog Scale) from 0 (no pain) to 10 (the most severe pain imaginable).</prim_outcome>
      <prim_outcome>The amount of Pethidine consumed. Timepoint: Until exiting recovery. Method of measurement: Record the amount of injected doses in the checklist.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Qazvin University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-03-01</approval_date>
        <contact_name>Ethics Committee of Qazvin University of Medical Sciences</contact_name>
        <contact_address>Research and Technology deputy, 1st Branch, Maudet Alley, Shahid Beheshti Blvd, Qazvin Qazvin Qazvin Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
